Pancreatic Cancer Research

ResearcherThe US Oncology NetworkActive in the last 2 years

Donald Richards

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2254-4514; OpenAlex author ID A5015961133. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  2. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Co-author DOI 10.1016/j.ejca.2024.113950↗
  3. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. Co-author DOI 10.1002/jcsm.12331↗
  4. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. Co-author DOI 10.1186/s12885-017-3131-x↗
  5. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  6. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  7. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic panc… First author DOI 10.1093/annonc/mds142↗
  8. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative… Co-author DOI 10.1007/s10637-009-9307-8↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taichi Kawabe · 1 shared paper, 2024 · strength 0.17
  2. Thomas Enzler · 1 shared paper, 2024 · strength 0.17
  3. Mark M. Zalupski · 1 shared paper, 2024 · strength 0.17
  4. Vaibhav Sahai · 1 shared paper, 2024 · strength 0.17
  5. Wells A. Messersmith · 1 shared paper, 2024 · strength 0.17
  6. Daniel D. Von Hoff · 2 shared papers, 2015–2017 · strength 0.09
  7. Talia Golan · 1 shared paper, 2018 · strength 0.09
  8. Salomon Marcello Stemmer · 1 shared paper, 2018 · strength 0.09
  9. Dick J. Richel · 1 shared paper, 2017 · strength 0.05
  10. Berta Laquente · 1 shared paper, 2017 · strength 0.05
  11. George Kim · 1 shared paper, 2017 · strength 0.05
  12. Emiliano Calvo Aller · 1 shared paper, 2017 · strength 0.05
  13. Tudor–Eliade Ciuleanu · 1 shared paper, 2017 · strength 0.05
  14. Stefano Cascinu · 1 shared paper, 2017 · strength 0.05
  15. Neeta D. Pandit-Taskar · 1 shared paper, 2015 · strength 0.03
  16. William A. Wegener · 1 shared paper, 2015 · strength 0.03
  17. Alexander Starodub · 1 shared paper, 2015 · strength 0.03
  18. Fa-Chyi Lee · 1 shared paper, 2015 · strength 0.03
  19. Bert H. O’Neil · 1 shared paper, 2015 · strength 0.03
  20. Eileen Mary O'Reilly · 1 shared paper, 2015 · strength 0.03
  21. Ronald Lee Korn · 1 shared paper, 2015 · strength 0.03
  22. Fadi Braiteh · 1 shared paper, 2015 · strength 0.03
  23. Allyson J. Ocean · 1 shared paper, 2015 · strength 0.03
  24. Ramesh K. Ramanathan · 1 shared paper, 2015 · strength 0.03
  25. Maeve Aine Lowery · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.